in re: mallinckrodt plc, et al. case no. (jointly

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re: MALLINCKRODT PLC, et al. Case No. (Jointly Administered): 20-12522 (JTD)

Reporting Period: June 26, 2021 – July 23, 2021

1

SUPPORTING DOCUMENTATION TO UST FORM 11-MOR

REQUIRED DOCUMENTS Form No. Document

Attached

Explanation

Attached

Schedule of Cash Receipts and Disbursements MOR-1 x

Statement of Operations MOR-2 x

Balance Sheet MOR-3 x

Case 20-12522-JTD Doc 3928-1 Filed 08/23/21 of 22

MOR NOTES



2

Notes to the Monthly Operating Report

General:

The report includes activity from the following Debtors and related Case Numbers:

Debtor Name Case No.

Mallinckrodt plc 20-12522 (JTD)

Acthar IP Unlimited Company 20-12524 (JTD)

IMC Exploration Company 20-12526 (JTD)

Infacare Pharmaceutical Corporation 20-12528 (JTD)

INO Therapeutics LLC 20-12530 (JTD)

Ludlow LLC 20-12533 (JTD)

MAK LLC 20-12536 (JTD)

Mallinckrodt APAP LLC 20-12537 (JTD)

Mallinckrodt ARD Finance LLC 20-12541 (JTD)

Mallinckrodt ARD Holdings Inc. 20-12543 (JTD)

Mallinckrodt ARD Holdings Limited 20-12546 (JTD)

Mallinckrodt ARD IP Unlimited Company 20-12549 (JTD)

Mallinckrodt ARD LLC 20-12551 (JTD)

Mallinckrodt Brand Pharmaceuticals LLC 20-12554 (JTD)

Mallinckrodt Buckingham Unlimited Company 20-12558 (JTD)

Mallinckrodt Canada ULC 20-12561 (JTD)

Mallinckrodt CB LLC 20-12564 (JTD)

Mallinckrodt Critical Care Finance LLC 20-12567 (JTD)

Mallinckrodt Enterprises Holdings, Inc. 20-12568 (JTD)

Mallinckrodt Enterprises LLC 20-12572 (JTD)

Mallinckrodt Enterprises UK Limited 20-12574 (JTD)

Mallinckrodt Group S.a.r.l. 20-12527 (JTD)

Mallinckrodt Holdings GmbH 20-12531 (JTD)

Mallinckrodt Hospital Products Inc. 20-12534 (JTD)

Mallinckrodt Hospital Products IP Unlimited Company 20-12538 (JTD)

Mallinckrodt International Finance SA 20-12540 (JTD)

Mallinckrodt International Holdings S.a.r.l. 20-12544 (JTD)

Mallinckrodt IP Unlimited Company 20-12548 (JTD)

Mallinckrodt LLC 20-12521 (JTD)

Mallinckrodt Lux IP S.a.r.l. 20-12553 (JTD)

Mallinckrodt Manufacturing LLC 20-12556 (JTD)

Mallinckrodt Pharma IP Trading Unlimited Company 20-12559 (JTD)

Mallinckrodt Pharmaceuticals Ireland Limited 20-12562 (JTD)

Mallinckrodt Pharmaceuticals Limited 20-12565 (JTD)

Mallinckrodt Quincy S.a.r.l. 20-12569 (JTD)


MOR NOTES



3

Debtor Name Case No.

Mallinckrodt UK Finance LLP 20-12573 (JTD)

Mallinckrodt U.K. Ltd 20-12576 (JTD)

Mallinckrodt US Holdings LLC 20-12578 (JTD)

Mallinckrodt US Pool LLC 20-12580 (JTD)

Mallinckrodt Veterinary, Inc. 20-12582 (JTD)

Mallinckrodt Windsor Ireland Finance Unlimited Company 20-12583 (JTD)

Mallinckrodt Windsor S.a.r.l. 20-12584 (JTD)

MCCH LLC 20-12525 (JTD)

MEH, Inc. 20-12529 (JTD)

MHP Finance LLC 20-12532 (JTD)

MKG Medical UK Ltd 20-12535 (JTD)

MNK 2011 LLC 20-12539 (JTD)

MUSHI UK Holdings Limited 20-12542 (JTD)

Ocera Therapeutics, Inc. 20-12545 (JTD)

Petten Holdings Inc. 20-12547 (JTD)

SpecGx Holdings LLC 20-12550 (JTD)

SpecGx LLC 20-12552 (JTD)

ST Operations LLC 20-12555 (JTD)

ST Shared Services LLC 20-12557 (JTD)

ST US Holdings LLC 20-12560 (JTD)

ST US Pool LLC 20-12563 (JTD)

Stratatech Corporation 20-12566 (JTD)

Sucampo Holdings Inc. 20-12570 (JTD)

Sucampo Pharma Americas LLC 20-12571 (JTD)

Sucampo Pharmaceuticals, Inc. 20-12575 (JTD)

Therakos, Inc. 20-12577 (JTD)

Vtesse LLC 20-12579 (JTD)

WebsterGx Holdco LLC 20-12581 (JTD)

Mallinckrodt Equinox Finance LLC 20-12523 (JTD)

Introduction: On October 12, 2020 (the “Petition Date”), Mallinckrodt plc and its affiliated debtors and debtors in

possession (collectively the “Debtors”) filed voluntary petitions for relief under chapter 11 of title 11 of the United States

Code, 11 U.S.C. §§ 101–1532 (the “Bankruptcy Code”) in the District of Delaware, thereby commencing cases jointly

administered as In re: Mallinckrodt plc, et al, No. 20-12522 (JTD). The Debtors continue to manage and operate their

businesses as debtors in possession under sections 1107 and 1108 of the Bankruptcy Code. On October 27, 2020, the United

States Trustee for the District of Delaware appointed an official committee of unsecured creditors and an official committee

of opioid related claimants pursuant to section 1102 of the Bankruptcy Code.

Case Progress - Since the Petition Date, the Debtors have continued fulfilling their bankruptcy court requirements and

also gained further creditor support for the Debtors’ previously announced Restructuring Support Agreement (“RSA”).

On December 23, 2020, the Debtors filed their Schedules of Assets and Liabilities, detailing assets and liabilities by

legal entity at the Petition Date, and their Statements of Financial Affairs, consisting of 32 questions disclosing sources of

income, transfers of property, lawsuits by creditors and other matters (collectively the “Schedules and Statements”). The


MOR NOTES



4

Debtors’ Schedules and Statements are available on the website of the Debtors’ claims agent at

https://restructuring.primeclerk.com/Mallinckrodt.

On February 12, 2021, the United States Trustee for the District of Delaware convened and presided at a continuation

of the meeting of creditors, pursuant to section 341 of the United States Bankruptcy Code. Members of the Debtors’

management team presented to creditors and to the United States Trustee and answered questions on the bankruptcy filing, on

the Schedules and Statements, and on other historical and current matters. Upon the Debtors’ completion of requests, the

United States Trustee filed a notice that the meeting was concluded, available on the website of the Debtors’ claims agent on

Docket #1560 at https://restructuring.primeclerk.com/Mallinckrodt/Home-DocketInfo.

On March 11, 2021, the Debtors reached an agreement to a joinder and amendment to the RSA with an ad hoc group

of first lien term lenders (the “Supporting First Lien Term Loan Lenders”) holding approximately $1.3 billion, in excess of

66.7% of each, of its outstanding senior secured term loans due in 2024 and 2025 (the “First Lien Term Loans”). This joinder

and amendment agreement received the required RSA approvals from other parties to the RSA including the supporting

unsecured noteholders, the government plaintiff ad hoc committee and the multi-state government entities group. This RSA

joinder and amendment provide how the lenders to the First Lien Term Loans are to be treated under the RSA and provide for

a mandatory prepayment of $114 million on the First Lien Term Loans for excess cash flow with respect to the fiscal year

ended December 25, 2020. Additional information on this joinder and amendment to the RSA is available on the website of

the Debtors’ claims agent on Docket # 1631 at https://restructuring.primeclerk.com/Mallinckrodt/Home-DocketInfo.

On April 20, 2021, the Debtors filed their Joint Plan of Reorganization of Mallinckrodt PLC and its Debtor Affiliates

Under Chapter 11 of the Bankruptcy Code (the “Plan”) on Docket # 2074 and filed their Disclosure Statement for Joint Chapter

11 Plan of Reorganization of Mallinckrodt PLC and its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (the

“Disclosure Statement”) on Docket # 2075, available along with subsequent Plan and Disclosure Statement filings at

https://restructuring.primeclerk.com/Mallinckrodt/Home-DocketInfo. The Plan provides for the classification and treatment

of claims and interests and the Disclosure Statement summarizes the terms of the Plan and certain Plan documents.

Accounting Principles: This Monthly Operating Report ("MOR") is unaudited and has been prepared solely for the

purpose of complying with the Debtors' obligations to provide monthly operating reports during these chapter 11 cases. This

MOR is not prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.

GAAP") and does not include all information and disclosures required by U.S. GAAP. The Debtors have prepared this MOR

using the best information presently available to them, which has been collected, maintained, and prepared in accordance with

their historical accounting practices. This MOR is, thus, true and accurate to the best of the Debtors’ knowledge, information

and belief based on current available data.

General Methodology: The Debtors prepared this MOR relying primarily upon the information set forth in their books

and records and may exclude information regarding non-Debtor affiliates. Additionally, the information furnished in this

report includes primarily normal recurring adjustments, but does not include all the adjustments necessary to ensure that the

quarterly and/or annual consolidated financial statements are in accordance with U.S. GAAP, including income tax accruals

that would typically be made. Furthermore, the monthly financial information contained herein has not been subjected to the

same level of accounting review and testing that the Debtors apply in the preparation of their quarterly and annual consolidated

financial information in accordance with U.S. GAAP. Accordingly, upon the application of such procedures, the Debtors

believe that the financial information may be subject to change, and these changes could be material.

This is the ninth filing of the MOR since the Petition Date and includes cash activity in MOR-1 for the fiscal month

ended July 23, 2021 and a Statement of Operations and Balance Sheet for fiscal July in MOR-2 and MOR-3. Any changes to

prior period balances will be reflected in the current month’s MOR. Nevertheless, in preparing this MOR, the Debtors made

best efforts to supplement the information set forth in their books and records with additional information concerning

transactions that may not have been identified therein.

Each Debtor closes its book and records on the last Friday of the month, based on a “52-53 week” year ending on the

last Friday of December.

Carrying Value of Assets: Unless otherwise noted, this MOR reflects the carrying values of the assets as recorded on

the Debtors’ books and records as of the end of the month and is not based upon an estimate of their current market value.

The Debtors reserve their right to amend or adjust the value of each asset set forth herein.


https://restructuring.primeclerk.com/Mallinckrodt

https://restructuring.primeclerk.com/Mallinckrodt/Home-DocketInfo



MOR NOTES



5

Prepetition Liabilities Subject to Compromise: As a result of the Chapter 11 Cases, the payment of certain

prepetition indebtedness may be subject to compromise or other treatment under a plan of reorganization. Generally, actions

to enforce or otherwise effect payment of pre-Chapter 11 liabilities are stayed. However, the Bankruptcy Court has authorized

the Debtors to pay certain prepetition claims subject to certain terms and conditions.

Intercompany Receivables and Payables: Mallinckrodt plc and its subsidiaries operate a complex global business

through an optimized multinational legal entity structure (the “Legal Entity Structure”) developed to conduct business, control

risks, and manage tax liabilities arising from the manufacturing and distribution of pharmaceuticals through the Specialty

Brands (“Brands”) and Specialty Generics (“SGx” or “Generics”) business segments. To effectively use the Legal Entity

Structure, the Debtors and Non-Debtor Affiliates engage in intercompany transactions which often include intra and inter

jurisdictional subsidiaries. These transactions result from trade activities as well as treasury transactions to manage global

cash requirements, tax liabilities, and capitalize entities with debt or equity. Intercompany transactions are governed by

distribution and supply agreements (primarily for cross-border activities), service agreements, Cash Management Agreements

(“CMA”), and loan documents. Transfer pricing used for product transfers, services, loan interest, and intellectual property

royalties is governed by arm’s-length standards and complies with debt document requirements for arm’s-length transactions.

Any transfer pricing used is monitored and documented regularly. Each intercompany transaction is recorded, and the

accounting records reflect the amounts due between the various global legal entities. Intercompany transactions are settled

either by book entry and/or through cash transfer. Intercompany indebtedness is subordinated to the extent required by the

credit documents. Intercompany balances between the Debtors and Non-Debtor Affiliates have not been eliminated in the

financial statements contained herein. No conclusion as to the legal obligation nor the related asset valuation associated with

these intercompany transactions and balances is made by the presentation herein. The Debtors are authorized to make certain

intercompany transactions with Debtor and non-Debtor affiliates as described more fully in the Final Order, (A) Authorizing

Continued Use of Existing Cash Management System, Including Maintenance of Existing Bank Accounts, Checks, and

Business Forms, (B) Authorizing Continuation of Existing Deposit Practices, (C) Waiving Certain U.S. Trustee Guidelines,

(D) Authorizing Continuation of Intercompany Transactions, and (E) Granting Superpriority Status to Postpetition

Intercompany Claims [D.I. 552].

Income Taxes: The Debtors’ income tax expense/(benefit), deferred income tax assets and liabilities, current and

noncurrent income tax liabilities, and income tax refunds receivable, including those attributable to the tax provisions of the

U.S. government enacted Coronavirus Aid, Relief, and Economic Security ("CARES") Act have not been reflected in the legal

entity financial statements in MOR-3 as such amounts are recorded on a consolidated basis. As of June 25, 2021, the total

combined Debtor-only net tax receivable (payable) balance was $153 million. Since June 25, 2021 through this reporting

period for the fiscal month ended July 23, 2021, there have been no significant changes to the combined Debtor-only net tax

receivable (payable) and subsequent changes will be reflected in MOR-1, and noted here, as deemed appropriate.

Past Performance: The results of operations contained herein are not necessarily indicative of results that may be

expected from any other period or for the full year and may not necessarily reflect the consolidated results of operations,

financial position and cash flows of the Debtors in the future. Intercompany transactions have not been eliminated in the

financial statements. For the reasons discussed above, the Debtors caution readers not to place undue reliance upon

information contained in this MOR.

SEC and Bankruptcy Court Filings: For further information, refer to the consolidated financial statements and

footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 25, 2020 and the

unaudited condensed consolidated financial statements and accompanying footnotes included in the Company’s Quarterly

Report on Form 10-Q for the fiscal quarter ended June 25, 2021, as filed with the SEC. Additional information about the

Chapter 11 Cases, court filings and claims information may be obtained on the website of the Debtors’ claims and noticing

agent at http://restructuring.primeclerk.com/Mallinckrodt.

Reservation of Rights: The Debtors hereby reserve all of their rights to dispute the validity, status, enforceability, or

executory nature of any claim amount, representation or other statement in this MOR and reserve the right to amend or

supplement this MOR, if necessary. In future periods, any changes to prior period balance will be reflected in the current

month’s MOR.


http://restructuring.primeclerk.com/Mallinckrodt

MOR NOTES



6

Notes to Supporting Documentation

Notes to MOR-1

Cash is received and disbursed by the Debtors as described in the Debtors' motion to approve continued use of their cash

management system which was granted on a final basis pursuant to an order entered by the Bankruptcy Court on November 19,

2020 [D.I. 552] and is consistent with the Debtor's historical cash management practices.

Cash activity related to intercompany transfers among the Debtors are excluded from cash receipts and disbursements.

Notes to MOR-1a:

Attached is a listing of the Debtor’s bank accounts, by account number, and the closing balances for the reporting

period. These book balances include outstanding checks and any reconciling items, which may result in a negative book balance.

Copies of the bank statements and cash disbursement journals were not included with the MOR due to the voluminous nature of

these reports and can be provided upon reasonable request in writing to counsel for the Debtors.

Notes to MOR-2 and MOR-3:

This MOR has been prepared on a consolidating basis for the Debtors. The financial information contained herein is

unaudited, limited in scope, covers a limited time period, and has been prepared solely for the purpose of complying with the

monthly reporting requirements for Chapter 11 debtors as required by the Bankruptcy Court and is in a format acceptable to the

United States Trustee for the District of Delaware (the "U.S. Trustee").

The MOR-2 Statement of Operations includes the Debtors’ fiscal month ended July 23, 2021, based upon a 52-53 week,

fiscal year. MOR-3 includes the Balance Sheet for the July fiscal month. As previously noted, this MOR was not prepared in

accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and does not include

all the information and disclosures required by U.S. GAAP. Therefore, there can be no assurance that the financial information

presented herein is complete, and readers are strongly cautioned not to place undue reliance on the MOR.

Notes to UST Form 11-MOR, Part 1 Cash Receipts and Disbursements:

Based on guidance received from the Office of the United States Trustee in connection with the completion of UST

Form 11-MOR Part 1, Cash Receipts and Disbursements, reported cash receipts and disbursements should exclude

intercompany, debtor-to-debtor, transactions. As a result, for those debtors with net intercompany cash outflows or inflows

during the reporting period, the ending cash balances reported on Form 11-MOR Part 1 will not agree with the ending cash

balances per the debtors’ bank statements or the debtors’ books and records. For additional information on ending cash

balances per the debtors’ books and records, see the attached listing of cash account balances per Schedule MOR-1a.

Notes to UST Form 11-MOR, Part 7 Questionnaire:

The Debtors have received approval to pay prepetition taxes and fee obligations, including, without limitation, sales,

use and excise taxes, franchise taxes, real and personal property taxes, income taxes, and certain other taxes due in the normal

course of business through certain First Day Motions. As such, applicable taxes had been paid when due except for amounts

which are in dispute, if any.


MOR-1

In re: MALLINCKRODT PLC, et al.

Case No. (Jointly Administered): 20-12522 (JTD)


7

Schedule of Cash Receipts and Disbursements

*Funds transferred between US Debtors have been excluded from the Summary of Cash Receipts and Disbursements amounts.

Schedule of Cash Receipts and Disbursements

TIME PERIOD: 6/26/2021 through 7/23/2021

Comparison to Consolidating CF

Operating Receipts $ 176,991,304

Total Operating Receipts 176,991,304

Vendor Payments (113,110,805)

Payroll & Benefits (37,207,182)

Total Operating Disbursements (150,317,987)

Operating Cash Flow 26,673,317

Total Debt Service (38,608,817)

Intercompany Receipts 9,945,627

Intercompany Disbursements (5,802,661)

Intra-Debtor Transfers, net -

Net Cash Flow before Restructuring Disbursements (7,792,534)

Professional Fees (21,458,342)

Total Restructuring Disbursements (21,458,342)

Net Cash Flow $ (29,250,876)


MOR-1



8

Summary of Cash Receipts and Disbursements

*Funds transferred between US Debtors have been excluded from receipt and disbursement amounts.

TIME PERIOD: 6/26/2021 through 7/23/2021 Checks

Debtor Name Case No. Receipts * Disbursements * Surplus / (Deficit)

Mallinckrodt plc 20-12522 $ - $ (2,598,494) $ (2,598,494)

Acthar IP Unlimited Company 20-12524 - (88) (88)

IMC Exploration Company 20-12526 - - -

Infacare Pharmaceutical Corporation 20-12528 - - -

INO Therapeutics LLC 20-12530 28,463,981 (4,529,440) 23,934,541

Ludlow LLC 20-12533 - - -

MAK LLC 20-12536 - - -

Mallinckrodt APAP LLC 20-12537 - - -

Mallinckrodt ARD Finance LLC 20-12541 - - -

Mallinckrodt ARD Holdings Inc. 20-12543 - - -

Mallinckrodt ARD Holdings Limited 20-12546 - (44) (44)

Mallinckrodt ARD IP Unlimited Company 20-12549 - (466) (466)

Mallinckrodt ARD LLC 20-12551 65,100,730 (38,030,461) 27,070,269

Mallinckrodt Brand Pharmaceuticals LLC 20-12554 - - -

Mallinckrodt Buckingham Unlimited Company 20-12558 - (77) (77)

Mallinckrodt Canada ULC 20-12561 1,049,841 (470,783) 579,058

Mallinckrodt CB LLC 20-12564 - - -

Mallinckrodt Critical Care Finance LLC 20-12567 - - -

Mallinckrodt Enterprises Holdings Inc 20-12568 - - -

Mallinckrodt Enterprises LLC 20-12572 200 (9,919,075) (9,918,875)

Mallinckrodt Enterprises UK Limited 20-12574 - (65) (65)

Mallinckrodt Group S.a.r.l. 20-12527 111 (147,299) (147,188)

Mallinckrodt Group S.à r.l., Luxembourg (LU) Schaffhausen Branch 20-12527 - (19,580) (19,580)

Mallinckrodt Holdings GmbH 20-12531 653 (1,336) (683)

Mallinckrodt Hospital Products Inc. 20-12534 792,416 - 792,416

Mallinckrodt Hospital Products IP Unlimited Company 20-12538 - (468) (468)

Mallinckrodt International Finance SA 20-12540 75,891 (20,932,910) (20,857,019)

Mallinckrodt International Holdings S.a.r.l. 20-12544 - (7,568) (7,568)

Mallinckrodt IP Unlimited Company 20-12548 - (160) (160)

Mallinckrodt LLC 20-12521 - - -

Mallinckrodt Lux IP S.a.r.l. 20-12553 735 (1,205) (470)

Mallinckrodt Manufacturing LLC 20-12556 - - -

Mallinckrodt Pharma IP Trading Unlimited Company 20-12559 1,618,624 - 1,618,624

Mallinckrodt Pharmaceuticals Ireland Limited 20-12562 4,422,109 (9,722,784) (5,300,676)

Mallinckrodt Pharmaceuticals Limited 20-12565 616,233 (732,253) (116,019)

Mallinckrodt Quincy S.a.r.l. 20-12569 - (17,489) (17,489)

Mallinckrodt UK Finance LLP 20-12573 - (69) (69)

Mallinckrodt UK Ltd 20-12576 - (38) (38)

Mallinckrodt US Holdings LLC 20-12578 - - -

Mallinckrodt US Pool LLC 20-12580 - - -

Mallinckrodt Veterinary, Inc. 20-12582 - - -

Mallinckrodt Windsor Ireland Finance Unlimited Company 20-12583 - (211) (211)

Mallinckrodt Windsor S.a.r.l. 20-12584 - (15,086) (15,086)

MCCH LLC 20-12525 - - -

MEH, Inc. 20-12529 - (8,013,914) (8,013,914)

MHP Finance LLC 20-12532 - - -

MKG Medical UK Ltd 20-12535 - (402) (402)

MNK 2011 LLC 20-12539 - - -

MUSHI UK Holdings Limited 20-12542 - (66) (66)

Ocera Therapeutics, Inc. 20-12545 - - -

Petten Holdings Inc 20-12547 - - -

SpecGx Holdings LLC 20-12550 - (113) (113)

SpecGx LLC 20-12552 57,367,769 (36,577,581) 20,790,188

ST Operations LLC 20-12555 - (37) (37)

ST Shared Services LLC 20-12557 1,593,213 (59,328,713) (57,735,500)

ST US Holdings LLC 20-12560 - - -

ST US Pool LLC 20-12563 1,512,094 (18,187,021) (16,674,927)

Stratatech Corporation 20-12566 40,416 - 40,416

Sucampo Holdings Inc. 20-12570 - - -

Sucampo Pharma Americas LLC 20-12571 9,463,237 (5,785,326) 3,677,911

Sucampo Pharmaceuticals, Inc. 20-12575 - - -

Therakos, Inc. 20-12577 14,818,680 (1,147,184) 13,671,495

Vtesse LLC 20-12579 - - -

WebsterGx Holdco LLC 20-12581 - - -

Mallinckrodt Equinox Finance LLC 20-12523 - - -

Total $186,936,931 ($216,187,807) ($29,250,876)


MOR-1a



9

Bank Account Information (page 1 of 2)

TIME PERIOD: 7/23/2021

*Book Balance may differ from Bank Balance due to items in-transit and other timing items.

Bank Account Information

Debtor Bank

Account No.

(last 4 digits)

Book Balance as

of 7/23/2021

Mallinckrodt Enterprises LLC Citibank -8599 $ (7,596)

Mallinckrodt LLC Citibank -8409 277,027

SpecGX LLC Citibank -5113 10,447,087

SpecGX LLC Citibank -6847 -

SpecGX LLC Citibank -8572 (823,827)

SpecGx LLC Citibank -0492 56,501,169

SpecGX Holdings LLC Citibank -7357 199,887

INO Therapeutics LLC Citibank -7003 553,402

INO Therapeutics LLC Citibank -6726 -

INO Therapeutics LLC Citibank -7444 (63,396)

Mallinckrodt ARD Holdings Inc. Citibank -3967 -

Mallinckrodt Hospital Products Inc. Citibank -3521 -

ST US Holdings LLC Citibank -3916 -

MEH, Inc. Citibank -8791 15,138

Stratatech Corporation Citibank -5148 -

ST Shared Services LLC Citibank -4915 -

ST Shared Services LLC Citibank -5791 (1,948,754)

ST Shared Services LLC Citibank -4493 909,061

ST US Pool LLC Citibank -9406 10,942,180

ST US Pool LLC Citibank -0785 155,009,708

ST US Pool LLC PNC -2405 -

Sucampo Pharma Americas LLC Citibank -8686 -

Sucampo Pharma Americas LLC Citibank -4409 5,873,749

Sucampo Pharmaceuticals, Inc. Citibank -2171 -

Therakos, Inc. Citibank -9564 -

Therakos, Inc. Citibank -2454 -

Therakos, Inc. Citibank -9012 646

Mallinckrodt Buckingham Unlimited Company Deutsche Bank Trust Company Americas -9892 229,316

Mallinckrodt International Finance SA Deutsche Bank Trust Company Americas -7999 65,379

Mallinckrodt International Finance SA ING Luxembourg -0000 26,711

Mallinckrodt International Finance SA Deutsche Bank AG -4000 15,462

Mallinckrodt International Finance SA Deutsche Bank Trust Company Americas -456.1 -

Mallinckrodt International Finance SA Deutsche Bank AG -4003 -

Mallinckrodt International Finance SA State Street Fund Services (Ireland) Limited -0792 -

Mallinckrodt International Finance SA Citibank -0214 130,301,000

Mallinckrodt International Finance SA State Street Fund Services (Ireland) Limited -4044 -

Mallinckrodt plc Deutsche Bank Trust Company Americas -8051 484,698

Mallinckrodt plc Deutsche Bank AG -8000 527,066

Mallinckrodt UK Finance LLP Deutsche Bank Trust Company Americas -2424 335,831

Mallinckrodt ARD Holdings Limited Deutsche Bank Trust Company Americas -1586 84,380

Mallinckrodt International Holdings S.a.r.l. ING Luxembourg -3010 22,593

Mallinckrodt International Holdings S.a.r.l. Deutsche Bank AG -2686 175,762

Mallinckrodt Quincy S.a.r.l. ING Luxembourg -3010 6,782

Mallinckrodt Quincy S.a.r.l. Citizens Bank -6253 -

Mallinckrodt Quincy S.a.r.l. Deutsche Bank AG -2678 241,267

Mallinckrodt Lux IP S.a.r.l. Deutsche Bank Trust Company Americas -1551 57,032

Mallinckrodt Lux IP S.a.r.l. ING Luxembourg -3000 36,175

Mallinckrodt Enterprises UK Limited Deutsche Bank Trust Company Americas -1594 300,458

Continued…


MOR-1a



10




*Book Balance may differ from Bank Balance due to items in-transit and other timing items.

Bank Account Information

Debtor Bank

Account No.

(last 4 digits)

Book Balance as

of 7/23/2021

Mallinckrodt Group S.a.r.l. Deutsche Bank AG -6000 $10,981,600

Mallinckrodt Group S.a.r.l. Deutsche Bank AG -6002 15,797



Mallinckrodt Group S.a.r.l. ING Luxembourg -0000 3,511

Mallinckrodt Group S.a.r.l. Deutsche Bank Trust Company Americas -8000 174,243

Mallinckrodt Group S.a.r.l. Deutsche Bank Trust Company Americas -7733 -


Mallinckrodt Group S.a.r.l. Citibank -0505 52,900,000

Mallinckrodt Group S.a.r.l. Citibank -0605 -

Mallinckrodt Group S.a.r.l., Luxembourg (LU) Schaffhausen Branch Deutsche Bank AG -0000 638,575

Mallinckrodt Group S.à r.l., Luxembourg (LU) Schaffhausen Branch Deutsche Bank AG -0001 51,084

Mallinckrodt Holdings GmbH Deutsche Bank Trust Company Americas -8027 71,037

Mallinckrodt Holdings GmbH Deutsche Bank AG -4000 749,277

Mallinckrodt Pharmaceuticals Ireland Limited Deutsche Bank AG -8000 5,900,221

Mallinckrodt Pharmaceuticals Ireland Limited Citibank Europe PLC, Dublin -8006 3,118,329

Mallinckrodt Pharmaceuticals Ireland Limited Deutsche Bank AG -0LDN 84,674

Mallinckrodt Pharmaceuticals Ireland Limited Deutsche Bank Trust Company Americas -1885 315,946,125

Mallinckrodt Pharmaceuticals Ireland Limited Citibank -2132 200,000,000

Mallinckrodt Pharmaceuticals Ireland Limited Deutsche Bank AG -0006 -

Mallinckrodt Windsor Ireland Finance Unlimited Company Deutsche Bank AG -0000 8,168

Mallinckrodt Windsor Ireland Finance Unlimited Company Deutsche Bank Trust Company Americas -9948 219,184

Mallinckrodt Windsor S.a.r.l. ING Luxembourg -0000 4,139

Mallinckrodt Windsor S.a.r.l. Deutsche Bank Trust Company Americas -0279 325,816

MKG Medical UK Ltd Deutsche Bank Trust Company Americas -9956 199,187

MKG Medical UK Ltd Deutsche Bank AG -0LDN 6,185

MUSHI UK Holdings Limited Deutsche Bank Trust Company Americas -1578 304,093

Acthar IP Unlimited Company Deutsche Bank AG -6000 3,197

Acthar IP Unlimited Company Deutsche Bank Trust Company Americas -7400 34,916

Mallinckrodt ARD LLC Citibank -5121 52,967,949

Mallinckrodt ARD LLC Citibank -3695 17,750,165

Mallinckrodt ARD IP Unlimited Company Deutsche Bank AG -6000 30,748

Mallinckrodt ARD IP Unlimited Company Deutsche Bank Trust Company Americas -9884 27,026

Mallinckrodt Canada ULC Citibank -3003 2,751,635

Mallinckrodt Canada ULC Citibank -3011 1,264,924

Mallinckrodt Hospital Products IP Unlimited Company Deutsche Bank AG -2000 30,869

Mallinckrodt Hospital Products IP Unlimited Company Deutsche Bank Trust Company Americas -9905 27,028

Mallinckrodt IP Unlimited Company Deutsche Bank AG -4001 1,677

Mallinckrodt IP Unlimited Company Deutsche Bank AG -4000 26,566

Mallinckrodt IP Unlimited Company Deutsche Bank Trust Company Americas -9913 26,187

Mallinckrodt Pharma IP Trading Unlimited Company Deutsche Bank Trust Company Americas -2555 370,919

Mallinckrodt Pharma IP Trading Unlimited Company Deutsche Bank AG -0000 1,879,451

Mallinckrodt Pharmaceuticals Limited Deutsche Bank AG -9500 613,838

Mallinckrodt Pharmaceuticals Limited Deutsche Bank Trust Company Americas -3929 8,692,186

Mallinckrodt UK Ltd Deutsche Bank Trust Company Americas -3937 27,525

ST Operations LLC Citibank -9422 680

Total Cash $ 1,049,602,405


MOR-2



11

Unaudited Statement of Operations (in 000's) page 1 of 6


The accompanying notes are an integral part of the financial statements.

$000s

Mallinckrodt PLCActhar IP Unlimited

Company

IMC Exploration

Company

InfaCare

Pharmaceutical

Corporation

INO Therapeutics

LLCLudlow LLC MAK LLC

Mallinckrodt APAP

LLC

Mallinckrodt ARD

Finance LLC

Mallinckrodt ARD

Holdings Inc.

Mallinckrodt ARD

Holdings Limited

Net sales $0 $0 $0 $0 $28,659 $0 $0 $11,975 $0 $0 $0

Cost of sales 104 0 0 0 3,754 0 0 8,622 0 0 0

Gross (loss) profit (104) 0 0 0 24,905 0 0 3,353 0 0 0

Operating expenses (income) 3,572 1 0 1 1,053 0 0 163 0 0 (0)

Operating (loss) income (3,676) (1) 0 (1) 23,852 0 0 3,190 0 0 0

Interest (expense) income, net 0 0 0 0 0 0 0 0 9,101 0 0

Other income (expense), net 1 0 0 0 0 0 0 0 0 0 0

Intercompany income (expense) 13 0 0 0 (35,092) 0 0 697 0 0 25

Reorganization items, net 7 0 0 0 0 0 0 0 0 0 0

(Loss) income from continuing operations before income taxes $ (3,656) $ (1) $ - $ (1) $ (11,240) $ - $ - $ 3,887 $ 9,101 $ - $ 26

Provision for income taxes 0 0 0 0 0 0 0 0 0 0 0

Income (loss) from continuing operations (3,656) (1) 0 (1) (11,240) 0 0 3,887 9,101 0 26

Gain (loss) from discontinued operations 0 0 0 0 0 0 0 0 0 0 0

Net (loss) income $ (3,656) $ (1) $ - $ (1) $ (11,240) $ - $ - $ 3,887 $ 9,101 $ - $ 26


MOR-2



12




$000s

Mallinckrodt ARD IP

Unlimited Company

Mallinckrodt ARD

LLC

Mallinckrodt Brand

Pharmaceuticals LLC

Mallinckrodt

Buckingham

Unlimited Company

Mallinckrodt Canada

ULCMallinckrodt CB LLC

Mallinckrodt Critical

Care Finance LLC

Mallinckrodt

Enterprises Holdings

Inc.

Mallinckrodt

Enterprises LLC

Mallinckrodt

Enterprises UK

Limited

Mallinckrodt Group

Sarl

Net sales $0 $45,184 $0 $0 $847 $0 $0 $0 $0 $0 $0

Cost of sales 0 1,654 0 0 181 0 0 0 0 0 0

Gross (loss) profit 0 43,530 0 0 666 0 0 0 0 0 0

Operating expenses (income) 1 3,900 0 2 24 0 0 0 24 (0) 157

Operating (loss) income (1) 39,631 0 (2) 643 0 0 0 (24) 0 (157)

Interest (expense) income, net 0 0 0 0 0 0 0 0 0 0 (5)

Other income (expense), net 0 5,005 0 0 0 0 0 0 0 0 0

Intercompany income (expense) 0 (28,867) 0 0 (929) 0 0 (6) 0 (1) 251


(Loss) income from continuing operations before income taxes $ (1) $ 15,768 $ - $ (2) $ (286) $ - $ - $ (6) $ (24) $ (0) $ 89


Income (loss) from continuing operations (1) 15,768 0 (2) (286) 0 0 (6) (24) (0) 89


Net (loss) income $ (1) $ 15,768 $ - $ (2) $ (286) $ - $ - $ (6) $ (24) $ (0) $ 89


MOR-2



13




$000s

Mallinckrodt

Holdings GmbH

Mallinckrodt

Hospital Products

Inc.

Mallinckrodt

Hospital Products IP

Unlimited Company

Mallinckrodt

International

Finance SA

Mallinckrodt

International

Holdings S.a.r.l.

Mallinckrodt IP

Unlimited CompanyMallinckrodt LLC

Mallinckrodt Lux IP

S.a.r.l.

Mallinckrodt

Manufacturing LLC

Mallinckrodt

Pharma IP Trading

Unlimited Company

Mallinckrodt

Pharmaceuticals

Ireland Limited

Net sales $0 $1,529 $0 $0 $0 $0 $0 $0 $0 $0 $0

Cost of sales 0 528 0 0 0 0 0 0 955 0 44,637

Gross (loss) profit 0 1,001 0 0 0 0 0 0 (955) 0 (44,637)

Operating expenses (income) 1 695 1 (393) 2 1 (26) (75) 20 35 5,927

Operating (loss) income (1) 305 (1) 393 (2) (1) 26 75 (975) (35) (50,563)

Interest (expense) income, net 0 0 0 (6,478) 0 0 0 0 0 0 0


Intercompany income (expense) 34 (4,833) 0 (90) (2) 0 0 962 265 1 175,215

Reorganization items, net 0 0 0 (427) 0 0 (16,318) 0 0 0 0

(Loss) income from continuing operations before income taxes $ 32 $ (4,528) $ (1) $ (6,602) $ (4) $ (1) $ (16,238) $ 1,037 $ (710) $ (35) $ 124,652


Income (loss) from continuing operations 32 (4,528) (1) (6,602) (4) (1) (16,238) 1,037 (710) (35) 124,652


Net (loss) income $ 32 $ (4,528) $ (1) $ (6,602) $ (4) $ (1) $ (16,238) $ 1,037 $ (710) $ (35) $ 124,652


MOR-2



14




$000s

Mallinckrodt

Pharmaceuticals

Limited

Mallinckrodt Quincy

S.a.r.l.

Mallinckrodt UK

Finance LLPMallinckrodt UK Ltd

Mallinckrodt US

Holdings LLC

Mallinckrodt US

Pool LLC

Mallinckrodt

Veterinary, Inc.

Mallinckrodt

Windsor Ireland

Finance Unlimited

Company

Mallinckrodt

Windsor S.a.r.l.MCCH LLC MEH, Inc.

Net sales $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Cost of sales 45 0 0 0 0 0 0 0 0 0 0

Gross (loss) profit (45) 0 0 0 0 0 0 0 0 0 0

Operating expenses (income) 921 (12) (1) (1) 79 34 2 0 1 0 11

Operating (loss) income (966) 12 1 1 (79) (34) (2) (0) (1) 0 (11)

Interest (expense) income, net 0 0 0 0 0 0 0 0 0 0 (11,566)


Intercompany income (expense) 0 (2) 18,472 0 0 0 0 (0) (3) 0 39


(Loss) income from continuing operations before income taxes $ (966) $ 10 $ 18,473 $ 1 $ (79) $ (34) $ (2) $ (0) $ (4) $ - $ (11,537)


Income (loss) from continuing operations (966) 10 18,473 1 (79) (34) (2) (0) (4) 0 (11,537)


Net (loss) income $ (966) $ 10 $ 18,473 $ 1 $ (79) $ (34) $ (2) $ (0) $ (4) $ - $ (11,537)


MOR-2



15




$000s

MHP Finance LLCMKG Medical UK

LTDMNK 2011 LLC

MUSHI UK Holdings

Ltd

Ocera Therapeutics,

Inc.Petten Holdings Inc SpecGx Holdings LLC SpecGX LLC ST Operations LLC

ST Shared Services

LLCST US Holdings LLC

Net sales $0 $0 $0 $0 $0 $0 $0 $24,931 $0 $0 $0

Cost of sales 0 0 0 0 0 0 0 24,269 2 1,540 0

Gross (loss) profit 0 0 0 0 0 0 0 662 (2) (1,540) 0

Operating expenses (income) 0 (2) 0 (0) 139 0 0 6,880 0 36,553 0

Operating (loss) income 0 2 0 0 (139) 0 (0) (6,218) (2) (38,092) 0

Interest (expense) income, net 0 0 0 0 0 0 0 0 0 528 0

Other income (expense), net 0 0 0 0 0 0 0 0 0 (1) 0

Intercompany income (expense) 0 (0) 0 (1) 0 0 0 2,985 0 11,884 0

Reorganization items, net 0 0 0 0 0 0 0 0 0 (17,748) 0

(Loss) income from continuing operations before income taxes $ - $ 1 $ - $ (0) $ (139) $ - $ (0) $ (3,233) $ (2) $ (43,429) $ -


Income (loss) from continuing operations 0 1 0 (0) (139) 0 (0) (3,233) (2) (43,429) 0


Net (loss) income $ - $ 1 $ - $ (0) $ (139) $ - $ (0) $ (3,233) $ (2) $ (43,429) $ -


MOR-2



16




$000s

ST US Pool LLCStratatech

Corporation

Sucampo Holdings

Inc.

Sucampo Pharma

Americas, LLC

Sucampo

Pharmaceuticals, Inc.Therakos, Inc. Vtesse LLC

WebsterGx Holdco

LLC

Mallinckrodt

Equinox Finance LLC

Net sales $0 $0 $0 $20,591 $0 $14,301 $0 $0 $0

Cost of sales 0 3 0 8,821 0 1,574 0 0 0

Gross (loss) profit 0 (3) 0 11,770 0 12,727 0 0 0

Operating expenses (income) 18 1,131 0 (62) 0 1,006 (76) 0 0

Operating (loss) income (18) (1,134) 0 11,833 0 11,721 76 0 0

Interest (expense) income, net 1 0 0 0 0 0 0 0 0

Other income (expense), net 0 0 0 0 0 0 0 0 0

Intercompany income (expense) 0 0 0 (592) 0 (9,624) 0 0 0

Reorganization items, net 0 0 0 0 0 0 0 0 0

(Loss) income from continuing operations before income taxes $ (17) $ (1,134) $ - $ 11,240 $ - $ 2,097 $ 76 $ - $ -

Provision for income taxes 0 0 0 0 0 0 0 0 0

Income (loss) from continuing operations (17) (1,134) 0 11,240 0 2,097 76 0 0

Gain (loss) from discontinued operations 0 0 0 0 0 0 0 0 0

Net (loss) income $ (17) $ (1,134) $ - $ 11,240 $ - $ 2,097 $ 76 $ - $ -


MOR-3



17

Unaudited Balance Sheet (in 000's) page 1 of 6



$000s Mallinckrodt PLCActhar IP Unlimited

Company

IMC Exploration

Company

InfaCare

Pharmaceutical

Corporation

INO Therapeutics

LLCLudlow LLC MAK LLC

Mallinckrodt APAP

LLC

Mallinckrodt ARD

Finance LLC

Mallinckrodt ARD

Holdings Inc.

Mallinckrodt ARD

Holdings Limited

CASH AND CASH EQUIVALENTS $ 1,012 $ 38 $ - $ - $ 490 $ - $ - $ - $ - $ - $ 84

ACCOUNTS RECEIVABLE - - - - 81,606 - - 24,404 - - -

INVENTORIES - - - - 9,782 - - 22,697 - - -

PREPAID EXPENSES AND OTHER CURRENT ASSETS 8,846 - - 13 918 - - 2,796 - - -

INTERCOMPANY RECEIVABLES 33,389 - - 126 9,054 - - 7,406 - - -

TOTAL CURRENT ASSETS $ 43,246 $ 38 $ - $ 139 $ 101,849 $ - $ - $ 57,302 $ - $ - $ 84

- - - - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET - - - - 26,887 - - 134,467 - - -

INTANGIBLE ASSETS, NET - - - - - - - - - - -

OTHER ASSETS 8,542 - - - 854 - - 4,735 - - -

INVESTMENT IN SUBSIDIARY 28,408,201 2,729,807 - - - 7,113,077 64,377 - 5,391,816 2,938,533 7,482,727

INTERCOMPANY LOAN RECEIVABLE 318,351 - 8 1,233 (75,416) (328,665) (44,439) 82,851 (149,002) (8,797) 679,776

TOTAL ASSETS $ 28,778,340 $ 2,729,845 $ 8 $ 1,372 $ 54,174 $ 6,784,412 $ 19,938 $ 279,356 $ 5,242,814 $ 2,929,735 $ 8,162,587

- - - - - - - - - - -

CURRENT MATURITIES OF LONG-TERM DEBT - - - - - - - - - - -

ACCOUNTS PAYABLE 57 - - 1 2,285 - - 2,753 - - -

ACCRUED PAYROLL AND PAYROLL RELATED COSTS - - - - 1,745 - - 1,846 - - -

ACCRUED INTEREST - - - - - - - - - - -

ACCRUED AND OTHER CURRENT LIABILITIES 2,485 18 - 40 2,910 - - 4,486 - - 23

INTERCOMPANY PAYABLE 0 - - - 159,818 - - - - - -

TOTAL CURRENT LIABILITIES $ 2,543 $ 18 $ - $ 41 $ 166,759 $ - $ - $ 9,085 $ - $ - $ 23

- - - - - - - - - - -

LONG-TERM DEBT - - - - - - - - - - -

PENSION AND POSTRETIREMENT BENEFITS - - - - - - - - - - -

ENVIRONMENTAL LIABILITIES - - - - - - - 3,024 - - -

INCOME TAXES PAYABLE - - - - - - - - - - -

OTHER LIABILITIES - - - - 0 - - 1,938 0 - -

LIABILITIES SUBJECT TO COMPROMISE 246 - - 21 11,694 15,339 - 457 - - -

INTERCOMPANY LOANS PAYABLE - - - - - - - - - - 200

TOTAL LIABILITIES $ 2,788 $ 18 $ - $ 62 $ 178,453 $ 15,339 $ - $ 14,504 $ 0 $ - $ 222

- - - - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ 28,775,552 $ 2,729,827 $ 8 $ 1,310 $ (124,279) $ 6,769,073 $ 19,938 $ 264,852 $ 5,242,814 $ 2,929,735 $ 8,162,365

- - - - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 28,778,340 $ 2,729,845 $ 8 $ 1,372 $ 54,174 $ 6,784,412 $ 19,938 $ 279,356 $ 5,242,814 $ 2,929,735 $ 8,162,587


MOR-3



18




$000sMallinckrodt ARD IP

Unlimited Company

Mallinckrodt ARD

LLC

Mallinckrodt Brand

Pharmaceuticals LLC

Mallinckrodt

Buckingham

Unlimited Company

Mallinckrodt Canada

ULCMallinckrodt CB LLC

Mallinckrodt Critical

Care Finance LLC

Mallinckrodt

Enterprises Holdings

Inc.

Mallinckrodt

Enterprises LLC

Mallinckrodt

Enterprises UK

Limited

Mallinckrodt Group

Sarl

CASH AND CASH EQUIVALENTS $ 58 $ 70,718 $ - $ 229 $ 4,017 $ - $ - $ - $ (8) $ 300 $ 65,343

ACCOUNTS RECEIVABLE - 60,513 - - 590 - - - - - -

INVENTORIES - 254,882 - - 521 - - - - - -

PREPAID EXPENSES AND OTHER CURRENT ASSETS - 3,874 - - 283 - - - 250 - 77

INTERCOMPANY RECEIVABLES - 7,223 - 1 28 - - - 100 - 32

TOTAL CURRENT ASSETS $ 58 $ 397,210 $ - $ 230 $ 5,438 $ - $ - $ - $ 342 $ 300 $ 65,453

- - - - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET - 742 - - 0 - - - - - -


OTHER ASSETS - 3,594 - - 547 - - 180 - - 19,025

INVESTMENT IN SUBSIDIARY - 326,766 5,557,721 18,574,244 - - - 5,114,595 2,237,341 - 256,023

INTERCOMPANY LOAN RECEIVABLE - (138,372) 148 0 - - 30,550 (58,777) 77,682 - 63,025

TOTAL ASSETS $ 58 $ 589,939 $ 5,557,869 $ 18,574,474 $ 5,985 $ - $ 30,550 $ 5,055,999 $ 2,315,365 $ 300 $ 403,526

- - - - - - - - - - -


ACCOUNTS PAYABLE - 7,185 - - 4 - - - 6,169 - 22

ACCRUED PAYROLL AND PAYROLL RELATED COSTS - 5,863 - - 2 - - - (0) - 194


ACCRUED AND OTHER CURRENT LIABILITIES 18 93,288 - 26 (68) - - - 721 23 67

INTERCOMPANY PAYABLE - 167,387 - 2 1,131 - - - 6,088 - (1)

TOTAL CURRENT LIABILITIES $ 18 $ 273,722 $ - $ 28 $ 1,069 $ - $ - $ - $ 12,978 $ 23 $ 283

- - - - - - - - - - -

LONG-TERM DEBT - - - - - - - - - - -


ENVIRONMENTAL LIABILITIES - - - - - - - - - - -


OTHER LIABILITIES - 1,273 - - - - 8,827 - - - 1,620

LIABILITIES SUBJECT TO COMPROMISE - 644,602 - - 79 - - 1,821,583 - - 15,121

INTERCOMPANY LOANS PAYABLE - - - - - - - 0 - 141 128,476

TOTAL LIABILITIES $ 18 $ 919,597 $ - $ 28 $ 1,148 $ - $ 8,827 $ 1,821,583 $ 12,978 $ 163 $ 145,499

- - - - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ 40 $ (329,658) $ 5,557,869 $ 18,574,446 $ 4,837 $ - $ 21,723 $ 3,234,416 $ 2,302,387 $ 137 $ 258,027

- - - - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 58 $ 589,939 $ 5,557,869 $ 18,574,474 $ 5,985 $ - $ 30,550 $ 5,055,999 $ 2,315,365 $ 300 $ 403,526


MOR-3



19




$000sMallinckrodt

Holdings GmbH

Mallinckrodt

Hospital Products

Inc.

Mallinckrodt

Hospital Products IP

Unlimited Company

Mallinckrodt

International

Finance SA

Mallinckrodt

International

Holdings S.a.r.l.

Mallinckrodt IP

Unlimited CompanyMallinckrodt LLC

Mallinckrodt Lux IP

S.a.r.l.

Mallinckrodt

Manufacturing LLC

Mallinckrodt

Pharma IP Trading

Unlimited Company

Mallinckrodt

Pharmaceuticals

Ireland Limited

CASH AND CASH EQUIVALENTS $ 820 $ - $ 58 $ 130,409 $ 198 $ 54 $ - $ 93 $ - $ 2,250 $ 525,049

ACCOUNTS RECEIVABLE - 4,922 - - - - - - - - 0

INVENTORIES - 4,527 - - - - - - 8,701 - 45,514

PREPAID EXPENSES AND OTHER CURRENT ASSETS - 800 - 23,395 - - 9,653 33 1 0 2,292

INTERCOMPANY RECEIVABLES - 0 - 4,547 - 0 9,999 2,647,222 4,531 3 640,722

TOTAL CURRENT ASSETS $ 820 $ 10,249 $ 58 $ 158,351 $ 198 $ 54 $ 19,652 $ 2,647,348 $ 13,232 $ 2,253 $ 1,213,578

- - - - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET - 28 - - - - 34,740 - 14,963 - 131,495

INTANGIBLE ASSETS, NET - - - - - - 35,014 - - - 5,183,165

OTHER ASSETS - 1,276 - - - - 82,169 - 4,135 - 2,471

INVESTMENT IN SUBSIDIARY 6,071 3,302,201 - 17,868,824 308,159 1,026,402 744,351 2,600 - 4,228,310 631

INTERCOMPANY LOAN RECEIVABLE 949,098 (11,503) - - - - (81,760) 13,308 3,889 16,501 0

TOTAL ASSETS $ 955,990 $ 3,302,250 $ 58 $ 18,027,176 $ 308,358 $ 1,026,457 $ 834,166 $ 2,663,257 $ 36,220 $ 4,247,064 $ 6,531,341

- - - - - - - - - - -

CURRENT MATURITIES OF LONG-TERM DEBT - - - 804,268 - - - - - - -

ACCOUNTS PAYABLE - 802 - 73 9 - - 38 1,543 14 9,417

ACCRUED PAYROLL AND PAYROLL RELATED COSTS - 799 - - - - - - - 58 3,287

ACCRUED INTEREST - - - 1,686 - - - - - - -

ACCRUED AND OTHER CURRENT LIABILITIES 341 4,121 17 174 5 18 61,971 865 2,154 61 41,466

INTERCOMPANY PAYABLE - (0) - 8,016 2 - 62,905 2,514,872 48 1,631 2,663,597

TOTAL CURRENT LIABILITIES $ 341 $ 5,722 $ 17 $ 814,216 $ 16 $ 18 $ 124,876 $ 2,515,774 $ 3,746 $ 1,764 $ 2,717,767

- - - - - - - - - - -

LONG-TERM DEBT - - - - - - - - - - -

PENSION AND POSTRETIREMENT BENEFITS - - - - - - 14,672 - - - -

ENVIRONMENTAL LIABILITIES - - - - - - 29,597 - - - -


OTHER LIABILITIES - 477 - 0 - - 3,112 - 2,719 - -

LIABILITIES SUBJECT TO COMPROMISE 12 31,510 - 1,681,186 - - 1,635,367 2 421 - 26,878

INTERCOMPANY LOANS PAYABLE 707 - - 1,957,280 - - - - - - 1,404

TOTAL LIABILITIES $ 1,059 $ 37,709 $ 17 $ 4,452,683 $ 16 $ 18 $ 1,807,625 $ 2,515,776 $ 6,885 $ 1,764 $ 2,746,049

- - - - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ 954,930 $ 3,264,542 $ 40 $ 13,574,493 $ 308,341 $ 1,026,439 $ (973,459) $ 147,481 $ 29,335 $ 4,245,301 $ 3,785,292

- - - - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 955,990 $ 3,302,250 $ 58 $ 18,027,176 $ 308,358 $ 1,026,457 $ 834,166 $ 2,663,257 $ 36,220 $ 4,247,064 $ 6,531,341


MOR-3



20




$000s

Mallinckrodt

Pharmaceuticals

Limited

Mallinckrodt Quincy

S.a.r.l.

Mallinckrodt UK

Finance LLPMallinckrodt UK Ltd

Mallinckrodt US

Holdings LLC

Mallinckrodt US

Pool LLC

Mallinckrodt

Veterinary, Inc.

Mallinckrodt

Windsor Ireland

Finance Unlimited

Company

Mallinckrodt

Windsor S.a.r.l.MCCH LLC MEH, Inc.

CASH AND CASH EQUIVALENTS $ 9,306 $ 248 $ 336 $ 28 $ - $ - $ - $ 227 $ 330 $ - $ 15

ACCOUNTS RECEIVABLE - - - - - - - - - - -

INVENTORIES - - - - - - - - - - -

PREPAID EXPENSES AND OTHER CURRENT ASSETS 632 - - - 6,699 - - - - - 583

INTERCOMPANY RECEIVABLES 2 - 2,514,861 - - - - - - - 18,780

TOTAL CURRENT ASSETS $ 9,939 $ 248 $ 2,515,197 $ 28 $ 6,699 $ - $ - $ 227 $ 330 $ - $ 19,378

- - - - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET 2,760 - - - - - - - - - -


OTHER ASSETS 3,741 - - - 12,883 - 1,490 - - - -

INVESTMENT IN SUBSIDIARY 14,001,503 14,455,252 - - - - - - 9,017,420 7,344,105 10,490,091

INTERCOMPANY LOAN RECEIVABLE - 5 18 - (5,646) (2,296,151) (4,139) - 19 (158,019) (53,398)

TOTAL ASSETS $ 14,017,943 $ 14,455,505 $ 2,515,215 $ 28 $ 13,936 $ (2,296,151) $ (2,650) $ 227 $ 9,017,769 $ 7,186,086 $ 10,456,071

- - - - - - - - - - -

CURRENT MATURITIES OF LONG-TERM DEBT - - - - - - - - - - 899,172

ACCOUNTS PAYABLE 324 1 - - - - - - 1 - 113

ACCRUED PAYROLL AND PAYROLL RELATED COSTS 1,336 - - - - - - - - - 6,519

ACCRUED INTEREST - - - - - - - - - - 9,683

ACCRUED AND OTHER CURRENT LIABILITIES 981 1,197 50 47 636 - 350 23 5 - 5,458

INTERCOMPANY PAYABLE 194 2 - - 933 0 539 - 2 - 7,112

TOTAL CURRENT LIABILITIES $ 2,835 $ 1,201 $ 50 $ 47 $ 1,569 $ 0 $ 889 $ 23 $ 9 $ - $ 928,057

- - - - - - - - - - -

LONG-TERM DEBT - - - - - - - - - - -


ENVIRONMENTAL LIABILITIES - - - - 17,167 - 2,531 - - - -


OTHER LIABILITIES 4,209 - - - - - - - - - 32,555

LIABILITIES SUBJECT TO COMPROMISE 100 2 - - 17,817 - 13 - - - 2,327,068

INTERCOMPANY LOANS PAYABLE - - - - - - - 23 105 - -

TOTAL LIABILITIES $ 7,144 $ 1,202 $ 50 $ 47 $ 36,554 $ 0 $ 3,433 $ 46 $ 113 $ - $ 3,287,680

- - - - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ 14,010,799 $ 14,454,303 $ 2,515,165 $ (20) $ (22,618) $ (2,296,151) $ (6,083) $ 181 $ 9,017,656 $ 7,186,086 $ 7,168,391

- - - - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 14,017,943 $ 14,455,505 $ 2,515,215 $ 28 $ 13,936 $ (2,296,151) $ (2,650) $ 227 $ 9,017,769 $ 7,186,086 $ 10,456,071


MOR-3



21




$000s MHP Finance LLCMKG Medical UK

LTDMNK 2011 LLC

MUSHI UK Holdings

Ltd

Ocera Therapeutics,

Inc.Petten Holdings Inc SpecGx Holdings LLC SpecGX LLC ST Operations LLC

ST Shared Services

LLCST US Holdings LLC

CASH AND CASH EQUIVALENTS $ - $ 205 $ - $ 304 $ - $ - $ 200 $ 66,401 $ 1 $ (1,040) $ -

ACCOUNTS RECEIVABLE - - - - - - - 198,205 - - -

INVENTORIES - - - - - - - 219,344 272,055 - -

PREPAID EXPENSES AND OTHER CURRENT ASSETS - - - - 2,800 - - 10,435 - 32,035 -

INTERCOMPANY RECEIVABLES - - - - - - - 22,725 167,371 25,164 120

TOTAL CURRENT ASSETS $ - $ 205 $ - $ 304 $ 2,800 $ - $ 200 $ 517,110 $ 439,427 $ 56,159 $ 120

- - - - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET - - - - - - - 336,422 - 52,610 -

INTANGIBLE ASSETS, NET - - - - - - - 72,725 - - -

OTHER ASSETS - - - - 105 - - 31,274 - 1,798 -

INVESTMENT IN SUBSIDIARY - - 5,557,721 7,482,426 - 2,047,752 744,351 140,851 - - 6,849,341

INTERCOMPANY LOAN RECEIVABLE 56 - - - (101,772) (329) (200) (181,953) - 59,253 (251,214)

TOTAL ASSETS $ 56 $ 205 $ 5,557,721 $ 7,482,730 $ (98,866) $ 2,047,423 $ 744,350 $ 916,429 $ 439,427 $ 169,820 $ 6,598,247

- - - - - - - - - - -


ACCOUNTS PAYABLE - - - - 304 - - 30,496 - 26,026 -

ACCRUED PAYROLL AND PAYROLL RELATED COSTS - - - - - - - 20,568 - 63,254 -


ACCRUED AND OTHER CURRENT LIABILITIES - 20 - 23 9 - - 45,403 - 80,737 -

INTERCOMPANY PAYABLE - - - - - - - 8,484 438,635 451 -

TOTAL CURRENT LIABILITIES $ - $ 20 $ - $ 23 $ 313 $ - $ - $ 104,952 $ 438,635 $ 170,467 $ -

- - - - - - - - - - -

LONG-TERM DEBT - - - - - - - - - - -


ENVIRONMENTAL LIABILITIES - - - - - - - 6,772 - - -


OTHER LIABILITIES 1,205 - - - - - - 12,090 - 6,143 -

LIABILITIES SUBJECT TO COMPROMISE - - - - 1,506 - - 26,265 - 11,569 -

INTERCOMPANY LOANS PAYABLE - 100 - 150 - - - - - - -

TOTAL LIABILITIES $ 1,205 $ 119 $ - $ 173 $ 1,818 $ - $ - $ 150,078 $ 438,635 $ 188,179 $ -

- - - - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ (1,149) $ 86 $ 5,557,721 $ 7,482,558 $ (100,685) $ 2,047,423 $ 744,350 $ 766,351 $ 792 $ (18,359) $ 6,598,247

- - - - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 56 $ 205 $ 5,557,721 $ 7,482,730 $ (98,866) $ 2,047,423 $ 744,350 $ 916,429 $ 439,427 $ 169,820 $ 6,598,247


MOR-3



22




$000s ST US Pool LLCStratatech

Corporation

Sucampo Holdings

Inc.

Sucampo Pharma

Americas, LLC

Sucampo

Pharmaceuticals, Inc.Therakos, Inc. Vtesse LLC

WebsterGx Holdco

LLC

Mallinckrodt

Equinox Finance LLC

CASH AND CASH EQUIVALENTS $ 165,952 $ - $ - $ 5,874 $ - $ 1 $ - $ - $ -

ACCOUNTS RECEIVABLE - - - 15,212 - 22,087 - - -

INVENTORIES - 6,114 - - - 18,684 - - -

PREPAID EXPENSES AND OTHER CURRENT ASSETS - 709 - 32,564 - 2 1,819 - -

INTERCOMPANY RECEIVABLES - - 0 - - 233 - - -

TOTAL CURRENT ASSETS $ 165,952 $ 6,823 $ 0 $ 53,649 $ - $ 41,007 $ 1,819 $ - $ -

- - - - - - - - -

PROPERTY, PLANT AND EQUIPMENT, NET - 7,325 - - - 4,033 - - -

INTANGIBLE ASSETS, NET - 99,800 - 390,283 - - - - -

OTHER ASSETS - 13,351 - 239 - 13 - - -

INVESTMENT IN SUBSIDIARY - - 94,433 61,587 294,434 3,098,389 - 0 -

INTERCOMPANY LOAN RECEIVABLE (166,032) (114,275) - 124,236 34,018 38,402 (161,912) - 1,020

TOTAL ASSETS $ (80) $ 13,024 $ 94,434 $ 629,994 $ 328,451 $ 3,181,843 $ (160,094) $ 0 $ 1,020

- - - - - - - - -

CURRENT MATURITIES OF LONG-TERM DEBT - - - - - - - - -

ACCOUNTS PAYABLE - 2,189 - 7 - 1,091 573 - -

ACCRUED PAYROLL AND PAYROLL RELATED COSTS - - - - - 492 - - -

ACCRUED INTEREST - - - - - - - - -

ACCRUED AND OTHER CURRENT LIABILITIES - 1,890 - 8,107 - 4,893 1,609 - -

INTERCOMPANY PAYABLE - - - 3,822 - 29,567 - - -

TOTAL CURRENT LIABILITIES $ - $ 4,078 $ - $ 11,936 $ - $ 36,043 $ 2,182 $ - $ -

- - - - - - - - -

LONG-TERM DEBT - - - - - - - - -

PENSION AND POSTRETIREMENT BENEFITS - - - - - - - - -

ENVIRONMENTAL LIABILITIES - - - - - - - - -

INCOME TAXES PAYABLE - - - - - - - - -

OTHER LIABILITIES - 5,913 - - - - - - -

LIABILITIES SUBJECT TO COMPROMISE - 2,197 - 127,219 127,210 3,835 1,047 - -

INTERCOMPANY LOANS PAYABLE - - - - - - - - -

TOTAL LIABILITIES $ - $ 12,188 $ - $ 139,155 $ 127,210 $ 39,878 $ 3,230 $ - $ -

- - - - - - - - -

TOTAL SHAREHOLDERS' EQUITY $ (80) $ 836 $ 94,434 $ 490,839 $ 201,242 $ 3,141,964 $ (163,323) $ 0 $ 1,020

- - - - - - - - -

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ (80) $ 13,024 $ 94,434 $ 629,994 $ 328,451 $ 3,181,843 $ (160,094) $ 0 $ 1,020


in re: mallinckrodt plc, et al. case no. (jointly

Documents